Progress and Prospects in Parkinson's Research/Symptoms/Azilect
AZILECT ® is prescribed as a supplement to levodopa for the treatment of Parkinson’s disease symptoms.
Active ingredients
[edit | edit source]
Rasagiline is an irreversible inhibitor of monoamine oxidase[1] used as a monotherapy in early Parkinson's disease or as an adjunct therapy in more advanced cases.[2] It is selective for MAO type B over type A by a factor of fourteen.[3]
Inactive ingredients
[edit | edit source]Mannitol
Colloidal anhydrous silica
Maize starch
Stearic acid
Talc
Most common adverse reactions to AZILECT
[edit | edit source]Very common (Affecting more tham 1 user im 10)
Dyskinesia
Headache
Common (Affecting 1 to 10 users in 100}
abdominal pain
falls
allergy
fever
flu (influenza)
general feeling of being unwell (malaise)
neeck pain
chest pain (angina pectoris)
orthostatic hypotension
decreased appetite
constipation
dry mouth
nausea and vomiting
flatulence
leucopenia(abnormal blood tests)
arthralgia (joint pain)
musculoskeletal pain
joint inflammation (arthritis)
carpal tunnel syndrome (weakness or numbness of the hands)
decreased weight
abnormal dreams
postural instability
depression
dizziness
dystonia (muscle contractions)
rhinitis (runny nose)
dermatitis (skin irritation)
conjunctivitis (eye irritation)
urinary urgency
Less common adverse reactions to AZILECT
[edit | edit source]{Affects 1 to 10 users in 1,000)
stroke (cerebrovascular accident)
heart attack (myocardial infarction)
blistering rash (vesiculobullous rash)
Drug interactions
[edit | edit source]AZILECT should not be taken concurrently with:-
monamine oxidase (MAO) inhibitors
pethidine
St. John's Wort
Further Reading
[edit | edit source]Search the scientific literature (Azilect)
|
|---|
|
Literature search:
|
References
[edit | edit source]- ↑ Oldfield V, Keating GM, Perry CM (2007). "Rasagiline: a review of its use in the management of Parkinson's disease". Drugs 67 (12): 1725–47. PMID 17683172.
- ↑ Gallagher DA, Schrag A (2008). "Impact of newer pharmacological treatments on quality of life in patients with Parkinson's disease". CNS Drugs 22 (7): 563–86. doi:10.2165/00023210-200822070-00003. PMID 18547126.
- ↑ Binda C, Hubálek F, Li M et al. (2005). "Binding of Rasagiline-related Inhibitors to Human Monoamine Oxidases: A Kinetic and Crystallographic Analysis". Journal of Medical Chemistry 48 (26): 8148–54. doi:10.1021/jm0506266. PMID 16366596. PMC 2519603. //www.ncbi.nlm.nih.gov/pmc/articles/PMC2519603/.